Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion type Assertion NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_head.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion wasGeneratedBy ECO_0000203 NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_provenance.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion wasDerivedFrom befree-2016 NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_provenance.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion SIO_000772 17270025 NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_provenance.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion evidence source_evidence_literature NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_provenance.
- NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_assertion description "[Patients with pulmonary adenocarcinoma carrying the epidermal growth factor receptor (EGFR) mutation tend to display dramatic clinical response to treatment with the EGFR tyrosine kinase inhibitor gefitinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591836.RABgtE1vOM16cXX3hFwmjqfSwPrf8ynt2gCPwesqNEX0U130_provenance.